CMI For Patients
YOU ARE UNIQUE AND SO IS YOUR CANCER.
No two tumors are alike. Therefore, it is imperative to have the most advanced, personalized treatment assessment available when making decisions. Caris Molecular Intelligence® can identify biomarkers in your tumor that provide invaluable information on whether your tumor may or may not respond to specific drugs or clinical trials.
The word “biomarker” can refer to many different compounds in the body that indicate something about your health. When people refer to cancer biomarkers, they are usually referring to proteins, genes, and other molecules at the genetic and molecular level that affect how cancer cells grow, multiply, die and respond to other compounds in the body. One potentially promising use of biomarkers today identifies therapies to which a particular patient’s cancer may or may not respond. Caris Molecular Intelligence can identify the biomarkers in your tumor and provide a list of cancer drugs that might be of clinical benefit. This information may be a powerful tool to help your physician make more informed treatment decisions in your fight against cancer.
Patient Navigators are available to help guide patients in understanding their Caris Molecular Intelligence® report. Patient navigators are equipped to answer questions regarding how the testing works, Explanation of Benefits (EOB) statement and financial options. If you are a patient and have questions about Caris Life sciences® or Caris Molecular Intelligence, please email PatientNavigator@carisls.com or call (888) 979-8669.
MyCancer is an educational resource for cancer patients and their caregivers, sponsored by Caris Life Sciences®.
The information presented on MyCancer.com is intended to provide cancer patients with information about molecular profiling services and the role these services can play in providing tumor-specific biomarker information and therapy associations to their oncologists to help inform cancer treatment decisions.
MyCancer can help answer questions related to molecular profiling whether the patient has just been diagnosed, is already in treatment, or looking at new options. If you or someone you know falls into any of these categories, we encourage you to visit this site and learn more about molecular profiling from a patient’s point of view. You can also follow MyCancer on Facebook and Twitter and hear more inspiring stories from cancer survivors who may have benefited from precision medicine in their journey.